Physician profile
Eric B Carlson
NPI 1316941206
$26,331.24
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,054 · 2020: $6,292 · 2021: $1,134 · 2022: $9,450 · 2023: $8,279 · 2024: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,000 · Food and Beverage: $1,428 · Travel and Lodging: $957 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,000.00 |
| Food and Beverage | $1,427.69 |
| Travel and Lodging | $956.86 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $20,641.03 | 2019-2023 | Watchman Access System, Bodyguardian, Avvigo Guidance System |
| Abbott Laboratories | $3,334.75 | 2019-2023 | Cardiomems, Mitraclip |
| E.R. Squibb & Sons, L.L.C. | $396.81 | 2019-2023 | Eliquis, Camzyos |
| Biotronik INC. | $236.27 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $151.62 | 2019-2023 | |
| Ge Healthcare | $148.35 | 2020 | |
| Janssen Pharmaceuticals, INC | $147.57 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $144.04 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $122.14 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $121.97 | 2019-2022 | |
| Abiomed | $104.17 | 2020-2021 | |
| Pfizer INC. | $96.45 | 2019-2023 | |
| Irhythm Technologies, INC. | $83.34 | 2023-2024 | Zio Xt Patch |
| Novo Nordisk INC | $79.37 | 2019-2021 | |
| Amarin Pharma, INC. | $78.81 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $67.66 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor |
| Amgen INC. | $43.58 | 2020-2023 | |
| Gilead Sciences, INC. | $43.58 | 2019 | |
| Medtronic, INC. | $34.89 | 2021-2023 | Corevalve Evolut R |
| Lundbeck LLC | $29.58 | 2019-2020 | |
| Aveo Pharmaceuticals, INC. | $29.54 | 2023 | Fotivda |
| Astellas Pharma US INC | $26.12 | 2019-2020 | |
| Karyopharm Therapeutics INC. | $25.78 | 2024 | Xpovio |
| Shockwave Medical, INC | $20.96 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $20.04 | 2021 | |
| Akcea Therapeutics, INC. | $19.67 | 2020 | |
| Beigene USA, INC. | $18.91 | 2023 | Brukinsa |
| Infobionic, INC | $14.92 | 2020 | |
| Edwards Lifesciences Corporation | $13.86 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.04 | 2021 | |
| Merck Sharp & Dohme LLC | $11.95 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Carlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.